PMID: 2502684Aug 1, 1989Paper

Enhancement of survival from murine polymicrobial peritonitis with increased abdominal abscess formation

The Journal of Surgical Research
W G CheadleH C Polk

Abstract

Muramyl dipeptide (MDP), a purified synthetic immune adjuvant, has been shown to increase murine intraabdominal abscess formation in a monomicrobial model using Bacteroides fragilis. This effect required live bacteria and was abolished by appropriate antibiotics. A polymicrobial model of peritonitis and abdominal abscess formation using Streptococcus fecalis, Escherichia coli, and B. fragilis was initially used to determine mortality rates at various concentrations and obtain an appropriate LD50. Animals were then pretreated with MDP or its inert buffer and underwent intraperitoneal injection of the appropriate bacterial suspension. Mortality and abdominal abscess formation were then assessed at 2 weeks after injection. There was a significant reduction in mortality (P less than 0.03) in mice treated with MDP compared to the controls. In surviving animals, there was also a significant increase in the number of animals forming abscesses (P less than 0.05) following treatment with MDP. This study has shown that nonspecific immune stimulation by MDP provided enhanced protection against a polymicrobial intraperitoneal challenge and paradoxically increased the formation of abdominal abscesses at the same time. This may be regarded a...Continue Reading

References

Aug 1, 1978·European Journal of Immunology·M FevrierP Liacopoulos
Sep 1, 1975·The Journal of Infectious Diseases·W M WeinsteinS L Gorbach
Sep 1, 1986·The Journal of Surgical Research·W G CheadleH C Polk
Jan 1, 1986·Archives of Surgery·G L BrownH C Polk
Aug 19, 1974·Biochemical and Biophysical Research Communications·F EllouzE Lederer
Feb 1, 1984·The British Journal of Surgery·J R AusobskyH C Polk
Jun 1, 1980·The Journal of Surgical Research·D E FryR D Rink

❮ Previous
Next ❯

Citations

Dec 1, 1990·Inflammation·S M BelotskyT I Snastina
Sep 11, 1991·Baillière's Clinical Gastroenterology·R N Gallinaro, H C Polk
Jan 14, 2010·The British Journal of Surgery·M QadanH C Polk
Feb 1, 1996·Journal of Pediatric Surgery·K P Lally, T K Stonum
Sep 1, 1992·Clinical and Experimental Immunology·S GalandiukH C Polk
Jul 1, 1994·Clinical Microbiology Reviews·A G Johnson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.